Live Advantage Bait, LLC

Hatchery Production Is One of the Largest Costs and Restraints to Fin Fish Aquaculture and Spawning Aids Are Ranked as a High Priority Drug Required by the Aquaculture Industry. Exogenous Hormone Administration Has Been Developed to Induce Maturation and Obtain Fertilized Eggs. While the GNRH Hormone and Slow-release Vehicle Are Not New, Their Combination Into a Commercialized Product That Can Work Be Used for a Range of Fish Sizes and an Innovative Application Gun to Control Accurate Dosing Are Novel.this Project Will Build on Phase I Research Which Demonstrated Slow Release Implants Can Yield 2-3X Higher Juvenile Fish Production in Hatcheries Compared to Current Products on the Market. This Project Aims to Commercialize This Implant Through the Accomplishment of Three Tasks: (1) Optimize the Hormone Active Ingredient Analogue to Be Used in the Final Implant Formulation (2) Conduct Studies Required for Fda Registration Including Drug Efficacy and Animal Toxicity and (3) Develop a New Implant Applicator Gun That Can Allow for Accurate Custom Implant Dosing. Objectives 1 and 2 Require Trials on Fish. Pinfish Will Be Used as the Benchmark Species With Florida Pompano and Bellgus Angelfish Also Utilized to Demonstrate Implant Expansion to Other Fish Species. Objective 3 Will Be a Collaboration Between the PD, an Industrial Designer and a Marketing Firm, With Prototypes Trialed at Five Different Commercial Aquaculture Farms. the Outcome of This Project Will Be Two Products on the Path to Commercialization: (1) a Spawning Implant and (2) an Innovative Applicator Gun.